昆泰公司报道：卫生保健投资者在药物开发过程中的的作用增加。
Quintiles report: Healthcare payers to get greater drug development role.
昆泰也将成为默克雪兰诺未来临床试验设计活动中的一个关键因素。
Quintiles also will be a key contributor to Merck Serono's future clinical trial design activities.
昆泰公司帮助生物制药公司在充满变化的环境中驾驭风险并获取机会。
Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant.
昆泰公司是财富500强，也是全球最大的生物制药研发与商业外包服务提供商。
QuintilesIMS, a Fortune 500 company, is the world's largest provider of biopharmaceutical development and commercial outsourcing services.
展望未来，昆泰将成为默克雪兰诺全球临床项目外包临床开发服务唯一的主要提供者。
Moving forward, Quintiles will be the sole primary provider of Merck Serono's outsourced clinical development services for its global clinical programs.
为了充分利用双方的专业知识，昆泰领导层将参与协作默克雪兰诺产品组合开发的战略决策过程。
To fully leverage the expertise of both organizations, leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the Merck Serono portfolio.
根据该协议，默克雪兰诺将塑造并领导其临床开发项目的战略，昆泰则指导临床试验的规划和执行。
Under this agreement, Merck Serono will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution.
昆泰在全球50多个国家拥有23，000名勤奋的专业员工，坚定不移地致力于为患者服务、安全保护和道德规范。
The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics.
昆汀·马泰尔往后跳了一尺。
昆汀·马泰尔往后跳了一尺。
应用推荐